| Boehringer Ingelheim’s Bonanza Month |
Abstract
pdf
|
|
Business Review Editor |
|
| Therapy Focus: Hypoxia-Selective Agents as Anticancer Drugs |
Abstract
pdf
|
|
Business Review Editor |
|
| Deal Making Spotlights on Big Pharma |
Abstract
pdf
|
|
Business Review Editor |
|
| Astellas Enters into Yet Another Agreement |
Abstract
pdf
|
|
Business Review Editor |
|
| Abraxis and AstraZeneca Exchange Agreements |
Abstract
pdf
|
|
Business Review Editor |
|
| Chelsea Augments its Pipeline |
Abstract
pdf
|
|
Business Review Editor |
|
| Immunomedics Relights its Therapeutic Potential |
Abstract
pdf
|
|
Business Review Editor |
|
| IPOs: Still the Exit Strategy of Choice? |
Abstract
|
|
Business Review Editor |
|
| AstraZeneca to Acquire Cambridge Antibody Technology |
Abstract
pdf
|
|
Business Review Editor |
|
| Kos to Market SkyePharma’s Flutiform™ |
Abstract
pdf
|
|
Business Review Editor |
|